EMA Authorised: Zilbrysq (zilucoplan) — UCB Pharma S.A.

View source ↗

Summary

The EMA authorised Zilbrysq (zilucoplan) from UCB Pharma S.A. for the treatment of myasthenia gravis. This marks regulatory approval for this therapy in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• ZILBRYSQ (ZILUCOPLAN)

Snippet

Status: Authorised. Therapeutic area: Myasthenia Gravis. MAH: UCB Pharma S.A.. Decision date: 19/03/2026